CANO250117P7000
- 6.68
- 0.000.00%
Cano Health Newsroom
Cano Health (CANO) Receives a Hold From Truist Financial
UBS Downgrades Cano Health to Sell, Lowers Price Target to $3.75
Cano Health Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Intellia Therapeutics (NTLA), Cano Health (CANO) and Ultragenyx Pharmaceutical (RARE)
UBS Adjusts Cano Health Price Target to $12 From $150, Maintains Neutral Rating
Analysts Offer Insights on Healthcare Companies: Cano Health (CANO), Personalis (PSNL) and Cingulate Inc (CING)
Analysts Conflicted on These Healthcare Names: Gritstone Oncology (GRTS) and Cano Health (CANO)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Inozyme Pharma (INZY), Ionis Pharmaceuticals (IONS) and Cano Health (CANO)
Truist Financial Reaffirms Their Hold Rating on Cano Health (CANO)
Cano Health Analyst Ratings
Citigroup Downgrades Cano Health to Neutral, Lowers Price Target to $0.8
Cano Health Analyst Ratings
Cano Health (CANO) Gets a Sell From Bank of America Securities
Citi Downgrades Cano Health (CANO) to a Hold
Truist Financial Keeps Their Hold Rating on Cano Health (CANO)
UBS Adjusts Cano Health Price Target to $1.50 From $1, Maintains Neutral Rating
Piper Sandler Maintains Underweight on Cano Health, Raises Price Target to $1
Credit Suisse Sticks to Their Hold Rating for Cano Health (CANO)
Credit Suisse Reiterates Neutral on Cano Health, Maintains $2.5 Price Target
UBS Adjusts Cano Health Price Target to $1 From $1.25, Maintains Neutral Rating